Search results
Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug...
Is Axsome Therapeutics Stock a Screaming Buy?
Motley Fool· 12 months agoAxsome Therapeutics (NASDAQ: AXSM) may have what it takes to escape this less-than-ideal fate. Since going public in 2015, Axsome's shares have...
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics’ AXSM shares have surged 118.4% in the past three months against the industry’s...
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
Zacks via Yahoo Finance· 10 months agoAxsome Therapeutics, Inc. AXSM incurred an adjusted loss $1.00 per share in the second quarter of...
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
Zacks via Yahoo Finance· 3 months agoAxsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth...
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
Zacks via Yahoo Finance· 1 year agoAxsome Therapeutics AXSM is progressing well with the launch of its first product, Auvelity...
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
Zacks via Yahoo Finance· 1 year agoAxsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The...
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics, Inc. AXSM incurred a loss of $1.03 per share (excluding intangible asset...
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?
Motley Fool· 1 year agoAxsome Therapeutics' (NASDAQ: AXSM) psychiatric drug Auvelity could reach blockbuster status by the...
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
Zacks via Yahoo Finance· 1 year agoAxsome Therapeutics, Inc. AXSM incurred an adjusted loss 22 cents per share in the first quarter of...